Monoclonal antibodies for treatment of osteoporosis
Drugs Today (Barc). 2023 Mar;59(3):195-204. doi: 10.1358/dot.2023.59.3.3453905.ABSTRACTOsteoporosis is a chronic disease with high unmet medical need. It is characterized by low bone mass and deteriorated bone architecture, leading to increased risk of fragility fractures, with vertebral and hip fractures representing the highest risk of morbidity and mortality. The baseline therapeutic approach to osteoporosis treatment has been based on adequate intake of calcium and supplementation of vitamin D. In this review, we focus on two approved monoclonal antibodies, romosozumab and denosumab, which have been shown to be efficie...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Kveta Kroupova Vladimir Palicka Jan Rosa Source Type: research

Anakinra as a potential treatment for COVID-19
Drugs Today (Barc). 2023 Mar;59(3):107-112. doi: 10.1358/dot.2023.59.3.3542446.ABSTRACTOn November 8, 2022, the United States Food and Drug Administration (FDA) issued an emergency use authorization for the interleukin-1 (IL-1) inhibitor anakinra for the treatment of patients with COVID-19 pneumonia. The authorization was specifically intended for patients requiring supplemental oxygen who are at risk of progression to respiratory failure and are likely to have an elevated plasma soluble urokinase plasminogen activator receptor. Anakinra is a modified, recombinant human IL-1 receptor antagonist used to treat rheumatoid art...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research

Cenegermin for the treatment of dry eye disease
Drugs Today (Barc). 2023 Mar;59(3):113-123. doi: 10.1358/dot.2023.59.3.3521858.ABSTRACTDry eye disease (DED) is the most common ocular surface disorder affecting millions of people worldwide. Due to its chronic nature, the management of DED still represents a challenge in the ophthalmic practice. Nerve growth factor (NGF), which is expressed along with its high-affinity TrkA receptor on the ocular surface complex, has been widely studied for the treatment of neurotrophic keratopathy, and a novel recombinant human NGF (rhNGF) has recently received full market authorization in this setting. Since NGF has shown in both in vit...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Giulia Coco Giulia Piccotti Vito Romano Lorenzo Ferro Desideri Aldo Vagge Carlo Enrico Traverso Marco Pellegrini Alice Bruscolini Marco Marenco Giuseppe Giannaccare Source Type: research

Mitapivat for sickle cell disease and thalassemia
Drugs Today (Barc). 2023 Mar;59(3):125-134. doi: 10.1358/dot.2023.59.3.3521880.ABSTRACTMitapivat, an oral first-in-class activator of erythrocyte pyruvate kinase (PKR), was first investigated in patients with pyruvate kinase deficiency (PKD), where it was found to improve hemoglobin (Hb) concentrations in patients who did not regularly receive transfusions and to reduce transfusion burden in patients who receive regular transfusions. It was approved in 2022 for the treatment of PKD and is being explored in other hereditary chronic conditions that are associated with hemolytic mechanisms of anemia, such as sickle cell disea...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Federica Pilo Emanuele Angelucci Source Type: research

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis
Drugs Today (Barc). 2023 Mar;59(3):135-167. doi: 10.1358/dot.2023.59.3.3419557.ABSTRACTIn recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention. It has become apparent from murine studies and clinical trials that due to its inhibitory effect on immunoregulation and its stimulatory action on promoting proinflammatory responses, IL-17 is an ideal cytokine to target for drug development, in order to cease its induction or eliminate IL-17-producing cells of any kind. Several monoclonal antibodies have been developed and tested as poten...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Theodora Simopoulou Sotirios G Tsiogkas Efterpi Zafiriou Dimitrios P Bogdanos Source Type: research

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
Drugs Today (Barc). 2023 Mar;59(3):169-177. doi: 10.1358/dot.2023.59.3.3507759.ABSTRACTNearly two-thirds of patients with non-small cell lung cancer (NSCLC) have locally advanced or metastatic disease at the time of diagnosis, and many patients with early-stage disease will eventually experience metastatic recurrence. In the absence of a known driver alteration, treatment of metastatic NSCLC is limited to immunotherapy with or without cytotoxic chemotherapy. For most patients with locally advanced unresectable NSCLC, the standard of care involves concurrent chemoradiation followed by consolidative immunotherapy. Several im...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Mandy Sakamoto Antonio Jimeno Source Type: research

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma
Drugs Today (Barc). 2023 Mar;59(3):179-193. doi: 10.1358/dot.2023.59.3.3542417.ABSTRACTOn January 25, 2022, the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). Pharmacodynamic data indicate that tebentafusp targets a specific HLA-A*02:01/gp100 complex, activating both CD4+/CD8+ effector and memory T cells that induce tumor cell death. Tebentafusp is administered to patients via intrav...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Zhijian Wang Yuhao Xie Jing-Quan Wang Yuanhui Cheng Joshua Fleishman Zhe-Sheng Chen Yun Chen Source Type: research

Monoclonal antibodies for treatment of osteoporosis
Drugs Today (Barc). 2023 Mar;59(3):195-204. doi: 10.1358/dot.2023.59.3.3453905.ABSTRACTOsteoporosis is a chronic disease with high unmet medical need. It is characterized by low bone mass and deteriorated bone architecture, leading to increased risk of fragility fractures, with vertebral and hip fractures representing the highest risk of morbidity and mortality. The baseline therapeutic approach to osteoporosis treatment has been based on adequate intake of calcium and supplementation of vitamin D. In this review, we focus on two approved monoclonal antibodies, romosozumab and denosumab, which have been shown to be efficie...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Kveta Kroupova Vladimir Palicka Jan Rosa Source Type: research

Anakinra as a potential treatment for COVID-19
Drugs Today (Barc). 2023 Mar;59(3):107-112. doi: 10.1358/dot.2023.59.3.3542446.ABSTRACTOn November 8, 2022, the United States Food and Drug Administration (FDA) issued an emergency use authorization for the interleukin-1 (IL-1) inhibitor anakinra for the treatment of patients with COVID-19 pneumonia. The authorization was specifically intended for patients requiring supplemental oxygen who are at risk of progression to respiratory failure and are likely to have an elevated plasma soluble urokinase plasminogen activator receptor. Anakinra is a modified, recombinant human IL-1 receptor antagonist used to treat rheumatoid art...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research

Cenegermin for the treatment of dry eye disease
Drugs Today (Barc). 2023 Mar;59(3):113-123. doi: 10.1358/dot.2023.59.3.3521858.ABSTRACTDry eye disease (DED) is the most common ocular surface disorder affecting millions of people worldwide. Due to its chronic nature, the management of DED still represents a challenge in the ophthalmic practice. Nerve growth factor (NGF), which is expressed along with its high-affinity TrkA receptor on the ocular surface complex, has been widely studied for the treatment of neurotrophic keratopathy, and a novel recombinant human NGF (rhNGF) has recently received full market authorization in this setting. Since NGF has shown in both in vit...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Giulia Coco Giulia Piccotti Vito Romano Lorenzo Ferro Desideri Aldo Vagge Carlo Enrico Traverso Marco Pellegrini Alice Bruscolini Marco Marenco Giuseppe Giannaccare Source Type: research

Mitapivat for sickle cell disease and thalassemia
Drugs Today (Barc). 2023 Mar;59(3):125-134. doi: 10.1358/dot.2023.59.3.3521880.ABSTRACTMitapivat, an oral first-in-class activator of erythrocyte pyruvate kinase (PKR), was first investigated in patients with pyruvate kinase deficiency (PKD), where it was found to improve hemoglobin (Hb) concentrations in patients who did not regularly receive transfusions and to reduce transfusion burden in patients who receive regular transfusions. It was approved in 2022 for the treatment of PKD and is being explored in other hereditary chronic conditions that are associated with hemolytic mechanisms of anemia, such as sickle cell disea...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Federica Pilo Emanuele Angelucci Source Type: research

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis
Drugs Today (Barc). 2023 Mar;59(3):135-167. doi: 10.1358/dot.2023.59.3.3419557.ABSTRACTIn recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention. It has become apparent from murine studies and clinical trials that due to its inhibitory effect on immunoregulation and its stimulatory action on promoting proinflammatory responses, IL-17 is an ideal cytokine to target for drug development, in order to cease its induction or eliminate IL-17-producing cells of any kind. Several monoclonal antibodies have been developed and tested as poten...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Theodora Simopoulou Sotirios G Tsiogkas Efterpi Zafiriou Dimitrios P Bogdanos Source Type: research

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
Drugs Today (Barc). 2023 Mar;59(3):169-177. doi: 10.1358/dot.2023.59.3.3507759.ABSTRACTNearly two-thirds of patients with non-small cell lung cancer (NSCLC) have locally advanced or metastatic disease at the time of diagnosis, and many patients with early-stage disease will eventually experience metastatic recurrence. In the absence of a known driver alteration, treatment of metastatic NSCLC is limited to immunotherapy with or without cytotoxic chemotherapy. For most patients with locally advanced unresectable NSCLC, the standard of care involves concurrent chemoradiation followed by consolidative immunotherapy. Several im...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Mandy Sakamoto Antonio Jimeno Source Type: research

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma
Drugs Today (Barc). 2023 Mar;59(3):179-193. doi: 10.1358/dot.2023.59.3.3542417.ABSTRACTOn January 25, 2022, the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). Pharmacodynamic data indicate that tebentafusp targets a specific HLA-A*02:01/gp100 complex, activating both CD4+/CD8+ effector and memory T cells that induce tumor cell death. Tebentafusp is administered to patients via intrav...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Zhijian Wang Yuhao Xie Jing-Quan Wang Yuanhui Cheng Joshua Fleishman Zhe-Sheng Chen Yun Chen Source Type: research

Monoclonal antibodies for treatment of osteoporosis
Drugs Today (Barc). 2023 Mar;59(3):195-204. doi: 10.1358/dot.2023.59.3.3453905.ABSTRACTOsteoporosis is a chronic disease with high unmet medical need. It is characterized by low bone mass and deteriorated bone architecture, leading to increased risk of fragility fractures, with vertebral and hip fractures representing the highest risk of morbidity and mortality. The baseline therapeutic approach to osteoporosis treatment has been based on adequate intake of calcium and supplementation of vitamin D. In this review, we focus on two approved monoclonal antibodies, romosozumab and denosumab, which have been shown to be efficie...
Source: Drugs of Today - February 27, 2023 Category: Drugs & Pharmacology Authors: Kveta Kroupova Vladimir Palicka Jan Rosa Source Type: research